Levofloxacin

Levofloxacin hydrochloride. Chemical name: (S)-(-)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-[1,4]-benzoxazine-6-carboxylic acid hydrochloride monohydrate.

This product is suitable for the following moderate and severe infections caused by sensitive bacteria: 1. Respiratory system infections: acute bronchitis, acute exacerbation of chronic bronchitis, diffuse bronchiolitis, bronchiectasis complicated with infection, pneumonia, tonsillitis (peritonsillar abscess); 2. Urinary system infections: pyelonephritis, complicated urinary tract infection, etc.; 3. Reproductive system infections: acute prostatitis, acute epididymitis, uterine cavity infection, uterine adnexitis, pelvic inflammatory disease (metronidazole can be used in combination when anaerobic infection is suspected); 4. .Skin and soft tissue infections: infectious impetigo, cellulitis, lymphangitis (adenitis), subcutaneous abscess, perianal abscess, etc.; 5. Intestinal infections: bacterial dysentery, infectious enteritis, Salmonella enteritis, typhoid and paratyphoid; sepsis, neutropenia and various infections in immunocompromised patients; 6. Other infections: mastitis, trauma, burns and postoperative wound infection, abdominal infection (combined with metronidazole when necessary), cholecystitis, cholangitis, bone and joint infections, and ENT infections, etc.

Intravenous drip: 4 vials per day for adults, divided into 2 intravenous drips. For patients with severe infection and those whose pathogens are less sensitive to this product (such as Pseudomonas aeruginosa), the maximum daily dose can be increased to 6 vials, divided into 2 intravenous drips. (Each time, dilute with 5% glucose injection or 0.9% sodium chloride injection and drip intravenously.) The dose can be appropriately increased or decreased according to the type and symptoms of infection.

During medication, digestive symptoms such as nausea, vomiting, abdominal discomfort, diarrhea, loss of appetite, abdominal pain, and bloating may occur; neurological symptoms such as insomnia, dizziness, and headache; rash, itching, erythema, and redness, itching, or phlebitis at the injection site may occur. Transient liver function abnormalities may also occur, such as increased blood transaminase and increased serum total bilirubin. The incidence of the above adverse reactions is between 0.1 and 5%. Occasionally, blood urea nitrogen rises, fatigue, fever, palpitations, abnormal taste, and vascular pain after injection are observed, which are generally tolerated and disappear quickly after the end of the course of treatment.

Store in a cool place.

Hebei Zhitong Biopharmaceutical Co., Ltd.

• Founded in:

  1998-08-06

• Address:

  No.1 Gucheng, Dingxing County, Hebei Province

• Tax NO.:

  91130600108345190C

• Registered Funds:

  127.5 million yuan

• Website:

  Log in to view

• Email:

  Log in to view